Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesEagle Pharmaceuticals Inc

Eagle Pharmaceuticals Inc

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
0.95 USD 0.00(0%)
Last update at 2026-11-05T14:30:00Z
Market Cap
3.29M
P/E
0.74

Momentum Score

…

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on manufacturing, developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company's product portfolio offers RYANODEX for malignant hyperthermia; and BELRAPZO and BENDEKA for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. It also produces PEMFEXY, a ready-to-dilute liquid form of pemetrexed injection, indicated in combination with cisplatin for the initial treatment of patients with malignant pleural mesothelioma and non-small cell lung cancer; BARHEMSYS, a selective dopamine-2 (D2) and dopamine-3 (D3) receptor antagonist indicated in adults for prevention of postoperative nausea and vomiting (PONV); BYFAVO, a benzodiazepine indicated for the induction and maintenance of procedural sedation in adults. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an anti-toxin agent in Phase 2 development for the treatment of severe pneumonia in combination with traditional antibacterial drugs; ENA-001 developed by Enalare, an agnostic respiratory stimulant for respiratory depression; EA-114, novel and proprietary formulation of fulvestrant developed for hormone-receptor-positive (HR+) metastatic breast cancer. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat cancer. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.95
Low
0.95
High
52 Week Price Range
0.00
Low
3.42
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Eagle Pharmaceuticals develops and commercializes injectable therapies for hospital and oncology settings, with a focus on acute-care and rare-disease treatments. Long-term growth may be supported by commercialization of marketed products, a clinical pipeline and business development that could diversify revenue and leverage stable hospital demand.
Key risks include revenue concentration in few products, generics/biosimilar competition, regulatory or clinical setbacks and reimbursement pressure in hospital settings.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.95
Dividend Yield
-
Revenue TTM
257.55M
Revenue Per Share
19.68
Gross Profit TTM
179.88M
Debt / Equity
0.27
ROE
4.88%
Net Debt
7.14M
ROCE
18.12%
Diluted EPS TTM
0.34

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 61.43M -4.55M 22.68M 22.00M 34.04M
Net income 35.64M -8.63M 11.99M 14.31M 31.90M
Selling general administrative 106.63M 75.32M 78.60M 76.37M 60.51M
Gross profit 221.67M 129.37M 142.34M 135.00M 151.40M
Reconciled depreciation 12.02M 3.76M 4.77M 4.65M 3.67M
Ebit 53.45M -2.91M 25.25M 21.82M 46.63M
Ebitda 65.48M 0.85M 30.02M 29.34M 50.30M
Depreciation and amortization 12.02M 3.76M 4.77M 7.52M 3.67M
Non operating income net other -15.48M -5.68M -7.70M 2.87M 0.16M
Operating income 53.45M -2.91M 25.25M 21.82M 36.62M
Other operating expenses 235.65M 168.78M 154.85M 174.08M 166.84M
Interest expense 4.04M 1.64M 2.58M 2.69M 2.74M
Tax provision 25.79M 4.08M 10.69M 7.68M 2.13M
Interest income 0.27M 0.56M 0.56M 2.17M 0.16M
Net interest income -3.77M -1.07M -2.02M -0.52M -2.58M
Non recurring 9.48M 10.65M 11.82M 13.01M 30.16M
Income tax expense 25.79M 4.08M 10.69M 7.68M 2.13M
Total revenue 316.61M 171.55M 187.80M 195.89M 213.31M
Total operating expenses 140.71M 126.60M 109.38M 113.18M 104.93M
Cost of revenue 94.94M 42.18M 45.47M 60.90M 61.92M
Total other income expense net 7.98M -1.64M -2.58M 0.18M -9.85M
Net income from continuing ops 35.64M -8.63M 11.99M 14.31M 31.90M
Net income applicable to common shares 35.64M -8.63M 11.99M 14.31M 31.90M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 406.16M 253.73M 253.19M 254.55M 238.60M
Intangible assets 118.33M 10.67M 12.92M 15.58M 18.10M
Other current assets 13.20M 11.89M 1.60M 15.10M 10.26M
Total liab 172.60M 77.28M 67.18M 75.38M 77.84M
Total stockholder equity 233.56M 176.45M 186.01M 179.17M 160.76M
Other current liab 85.84M 6.97M 3.08M 2.30M 1.81M
Common stock 0.02M 0.02M 0.02M 0.02M 0.02M
Capital stock 0.02M 0.02M 0.02M 0.02M 0.02M
Retained earnings 111.50M 75.86M 84.49M 72.50M 58.19M
Other liab 3.79M 2.90M 3.96M 3.00M -
Good will 45.03M 39.74M 39.74M 39.74M 39.74M
Other assets 52.88M 29.08M 32.39M 13.86M 14.52M
Cash 55.32M 97.66M 103.16M 109.78M 78.79M
Total current liabilities 111.09M 74.38M 38.09M 38.82M 39.69M
Current deferred revenue - 25.36M 20.74M 26.06M 21.71M
Net debt 7.14M -72.05M -66.06M -71.22M -34.39M
Short term debt 6.25M 25.61M 8.00M 5.00M 6.25M
Short long term debt 6.25M 25.61M 8.00M 5.00M 6.25M
Short long term debt total 62.47M 25.61M 37.09M 38.56M 44.41M
Other stockholder equity 123.15M 100.67M 101.50M 106.66M 102.56M
Property plant equipment 1.17M 1.64M 2.08M 2.20M 2.40M
Total current assets 188.75M 172.61M 166.06M 179.45M 163.84M
Net tangible assets 70.20M 126.04M 133.35M 123.85M 102.92M
Net receivables 72.44M 41.15M 51.12M 48.00M 66.49M
Long term debt 56.22M - 25.14M 33.56M 38.16M
Inventory 47.79M 21.91M 8.07M 6.57M 8.30M
Accounts payable 18.99M 16.43M 6.27M 5.46M 9.92M
Accumulated other comprehensive income -1.11M -0.09M - -4.32M -3.35M
Common stock total equity 0.02M 0.02M 0.02M 0.02M 0.02M
Retained earnings total equity 111.50M 75.86M 84.49M 72.50M 58.19M
Treasury stock -243.12M -225.11M -203.90M -171.86M -153.90M
Non currrent assets other 25.73M 10.28M 17.21M 3.91M 0.69M
Non current assets total 217.41M 81.13M 87.12M 75.11M 74.76M
Capital lease obligations 5.32M 4.21M 3.96M 3.00M -
Long term debt total 56.22M - 25.14M 33.56M 38.16M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -86.83M -5.32M -18.25M -0.78M -0.13M
Change to liabilities 46.55M 17.93M -3.62M -0.39M 6.06M
Total cashflows from investing activities -86.83M -5.32M -18.25M -0.78M -0.13M
Net borrowings 11.40M -8.00M -5.00M -6.33M -3.75M
Total cash from financing activities -6.21M -28.39M -37.87M -24.23M -88.12M
Change to operating activities 19.80M 3.68M 4.63M -1.37M 12.40M
Net income 35.64M -8.63M 11.99M 14.31M 31.90M
Change in cash -42.34M -5.50M -6.62M 30.98M -35.87M
Begin period cash flow 97.66M 103.16M 109.78M 78.79M 114.66M
End period cash flow 55.32M 97.66M 103.16M 109.78M 78.79M
Total cash from operating activities 50.70M 28.22M 49.50M 55.99M 52.38M
Depreciation 12.02M 3.76M 4.77M 4.65M 3.67M
Other cashflows from investing activities -86.65M -5.00M -17.50M -17.50M -17.50M
Change to inventory -8.34M -13.83M -1.51M 1.74M -5.56M
Change to account receivables -30.83M 9.53M -3.11M 18.48M -12.66M
Sale purchase of stock -18.00M -21.21M -35.00M -17.96M -73.11M
Other cashflows from financing activities 79.03M 0.82M 112.13M -0.26M -11.26M
Change to netincome 17.73M 21.42M 28.55M 22.15M 24.32M
Capital expenditures 0.18M 0.32M 0.75M 0.78M 0.13M
Change receivables -30.83M 9.53M -3.11M 18.48M -12.66M
Cash flows other operating -22.54M -2.44M 13.25M -5.44M 4.27M
Cash and cash equivalents changes -42.34M -5.50M -6.62M 30.98M -35.87M
Change in working capital -16.40M 9.54M 0.82M 14.39M -7.89M
Stock based compensation 16.45M 19.55M 24.76M 22.00M 19.08M
Other non cash items 11.31M 7.61M 8.68M 0.48M 8.09M
Free cash flow 50.52M 27.90M 48.75M 55.21M 52.25M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
EGRX
Eagle Pharmaceuticals Inc		 -
-%		 0.95 0.74 11.34 0.01 0.16 0.38 1.75
MKKGY
Merck KGaA ADR		 -0.22
0.66%		 33.17 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 -2.76
1.62%		 167.12 24.86 15.11 3.13 1.98 3.08 18.89
TAK
Takeda Pharmaceutical Co Ltd ADR		 -0.17
0.80%		 21.02 - 10.96 0.01 1.20 2.94 23.11
TKPHF
Takeda Pharmaceutical Co. Ltd.		 -
-%		 41.85 - 10.66 0.01 1.16 2.94 23.11

Profile*

Eagle Pharmaceuticals Inc

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on manufacturing, developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company's product portfolio offers RYANODEX for malignant hyperthermia; and BELRAPZO and BENDEKA for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. It also produces PEMFEXY, a ready-to-dilute liquid form of pemetrexed injection, indicated in combination with cisplatin for the initial treatment of patients with malignant pleural mesothelioma and non-small cell lung cancer; BARHEMSYS, a selective dopamine-2 (D2) and dopamine-3 (D3) receptor antagonist indicated in adults for prevention of postoperative nausea and vomiting (PONV); BYFAVO, a benzodiazepine indicated for the induction and maintenance of procedural sedation in adults. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an anti-toxin agent in Phase 2 development for the treatment of severe pneumonia in combination with traditional antibacterial drugs; ENA-001 developed by Enalare, an agnostic respiratory stimulant for respiratory depression; EA-114, novel and proprietary formulation of fulvestrant developed for hormone-receptor-positive (HR+) metastatic breast cancer. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat cancer. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.

50 Tice Boulevard, Woodcliff Lake, NJ, United States, 07677

201 326 5300

https://www.eagleus.com

134

Name Title Year Born
Mr. Scott L. Tarriff Founder, Pres, CEO & Director 1960
Mr. Brian Joseph Cahill Chief Financial Officer 1969
Mr. Ryan Debski Exec. VP, Gen. Counsel & Chief Compliance Officer NA
Mr. Daniel O'Connor Exec. VP, Chief Strategy Officer & Head of Corp. Devel. 1980
Mr. John Kimmet Exec. VP of Marketing Oncology & Acute Care NA
Dr. Valentin R. Curt M.D. Sr. VP of Clinical Drug Devel. NA
Dr. Gaozhong Zhu Ph.D. Sr. VP of Pharmaceutical Devel. NA
Ms. Debra M. Hussain Sr. VP & Head of Commercial NA
Mr. Reiner Nowak Exec. NA
Mr. Michael Graves Interim Principal Executive Officer & Executive Chairman of the Board 1963

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…